1. Anwar H, Khan QU, Nadeem N, Pervaiz I, Ali M, Cheema FF. Epileptic seizures. Discoveries. 2020; 8(2). [DOI:10.15190/d.2020.7]

2. Pfisterer U, Petukhov V, Demharter S, Meichsner J, Thompson JJ, Batiuk MY, et al. Identification of epilepsy-associated neuronal subtypes and gene expression underlying epileptogenesis. Nature communications. 2020; 11(1): 1-19. [DOI:10.1038/s41467-020-18752-7]

3. Yaghoubi F, Jafarian M, Gorji A. The Anticonvulsant Effect of the Ketogenic Diet in the Treatment of Epilepsy. The Neuroscience Journal of Shefaye Khatam. 2020, 9(1): 200-09. [DOI:10.52547/shefa.9.1.200]

4. Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics. 2012; 129(2): 256-64. [DOI:10.1542/peds.2010-1371]

5. Lagae L. The need for broad spectrum and safe anti-epileptic drugs in childhood epilepsy. Acta Neurol Belg. 2009; 109(3): 167-70.

6. Kobayashi K, Endoh F, Ohmori I, Akiyama T. Action of antiepileptic drugs on neurons. Brain and Development. 2020; 42(1): 2-5. [DOI:10.1016/j.braindev.2019.07.006]

7. Abumurad S, Issa NP, Wu S, Rose S, Esengul YT, Nordli D, et al. Laser interstitial thermal therapy for NPRL3-related epilepsy with multiple seizure foci: A case report. Epilepsy & Behavior Reports. 2021: 100459. [DOI:10.1016/j.ebr.2021.100459]

8. Rogawski MA, Löscher W, Rho JM. Mechanisms of action of antiseizure drugs and the ketogenic diet. Cold Spring Harbor perspectives in medicine. 2016; 6(5): a022780. [DOI:10.1101/cshperspect.a022780]

9. Abdolmaleki A, Moghimi A, Ghayour MB, Rassouli MB. Evaluation of neuroprotective, anticonvulsant, sedative and anxiolytic activity of citicoline in rats. European journal of pharmacology. 2016; 789: 275-9. [DOI:10.1016/j.ejphar.2016.07.048]

10. Soluki M, Mahmoudi F, Abdolmaleki A, Asadi A, Sabahi Namini A. Cerium oxide nanoparticles as a new neuroprotective agent to promote functional recovery in a rat model of sciatic nerve crush injury. British Journal of Neurosurgery. 2020: 1-6. [DOI:10.1080/02688697.2020.1864292]

11. Schipper S, Aalbers M, Rijkers K, Swijsen A, Rigo J, Hoogland G, et al. Tonic GABA A receptors as potential target for the treatment of temporal lobe epilepsy. Molecular neurobiology. 2016; 53(8): 5252-65. [DOI:10.1007/s12035-015-9423-8]

12. Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy research. 2015; 110: 189-205. [DOI:10.1016/j.eplepsyres.2014.11.021]

13. Powell KL, Cain SM, Snutch TP, O'Brien TJ. Low threshold T‐type calcium channels as targets for novel epilepsy treatments. British journal of clinical pharmacology. 2014; 77(5): 729-39. [DOI:10.1111/bcp.12205]

14. Nilo A, Pauletto G, Gigli GL, Vogrig A, Dolso P, Valente M. Perampanel as add-on therapy in epilepsies with known etiology: A single center experience with long-term follow-up. Epilepsy & Behavior Reports. 2021; 15: 100393. [DOI:10.1016/j.ebr.2020.100393]

15. Cherian A, Shetty SC, Divya K, Pavuluri H. Weekly methotrexate may reduce valproate levels causing relapse of genetic generalized epilepsy. Epilepsy & Behavior Reports. 2021; 16. [DOI:10.1016/j.ebr.2021.100457]

16. Dreischmeier E, Zuloaga A, Kotloski RJ, Karasov AO, Gidal BE. Levetiracetam-associated irritability and potential role of vitamin B6 use in veterans with epilepsy. Epilepsy & Behavior Reports. 2021; 16: 100452. [DOI:10.1016/j.ebr.2021.100452]

17. Upadhaya PG, Pulakkat S, Patravale VB. Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management. Drug delivery and translational research. 2020. [DOI:10.1007/s13346-020-00747-y]

18. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2(1): 3-14. [DOI:10.1602/neurorx.2.1.3]

19. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine. 2000; 342(5): 314-19. [DOI:10.1056/NEJM200002033420503]

20. Bennewitz MF, Saltzman WM. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics. 2009; 6(2): 323-36. [DOI:10.1016/j.nurt.2009.01.018]

21. Sonvico F, Clementino A, Buttini F, Colombo G, Pescina S, Stanisçuaski Guterres S, et al. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics. 2018; 10(1): 34. [DOI:10.3390/pharmaceutics10010034]

22. Tayab ZR, Hochhaus G. Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. Expert opinion on drug delivery. 2005; 2(3): 519-32. [DOI:10.1517/17425247.2.3.519]

23. Fisher RS, Chen DK. New routes for delivery of anti-epileptic medications. Acta Neurologica Taiwanica. 2006; 15(4): 225.

24. Heiss JD, Walbridge S, Morrison P, Hampton RR, Sato S, Vortmeyer A, et al. Local distribution and toxicity of prolonged hippocampal infusion of muscimol. Journal of neurosurgery. 2005; 103(6): 1035-45. [DOI:10.3171/jns.2005.103.6.1035]

25. Stein AG, Eder HG, Blum DE, Drachev A, Fisher RS. An automated drug delivery system for focal epilepsy. Epilepsy research. 2000; 39(2): 103-14. [DOI:10.1016/S0920-1211(99)00107-2]

26. Anschel DJ, Ortega E, Fisher RS. Diazepam prophylaxis for bicuculline-induced seizures: a rat dose-response model. Neuroscience letters. 2004; 356(1): 66-8. [DOI:10.1016/j.neulet.2003.10.082]

27. Litt B, Echauz J. Prediction of epileptic seizures. The Lancet Neurology. 2002; 1(1): 22-30. [DOI:10.1016/S1474-4422(02)00003-0]

28. Dowd E, Monville C, Torres EM, Wong LF, Azzouz M, Mazarakis ND, et al. Lentivector‐mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. European Journal of Neuroscience. 2005; 22(10): 2587-95. [DOI:10.1111/j.1460-9568.2005.04414.x]